Patient Education Sheet Library
Search Results
Acalabrutinib, Venetoclax, and Obinutuzumab
The combination of acalabrutinib, venetoclax, and obinutuzumab is used for chronic lymphocytic leukemia (CLL) or…
Treatment Given by Infusion Treatment Taken by MouthDownloads:
Download (English)Afamitresgene Autoleucel
Amitresgene autoleucel is used for synovial sarcoma.
Treatment Given by InfusionDownloads:
Tisagenlecleucel
Tisagenlecleucel is used for acute lymphoblastic leukemia (ALL), follicular lymphoma (FL), and large B-cell lymphoma…
Treatment Given by InfusionDownloads:
Crizanlizumab
Crizanlizumab is used for people who have sickle cell disease to help reduce how often…
Treatment Given by InfusionDownloads:
Axicabtagene Ciloleucel
Axicabtagene ciloleucel is used for follicular lymphoma (FL) and large B-cell lymphoma (LBCL).
Treatment Given by InfusionDownloads:
Lisocabtagene Maraleucel
Lisocabtagene maraleucel is used for chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), large B-cell lymphoma…
Treatment Given by InfusionDownloads:
Brexucabtagene Autoleucel
Brexucabtagene autoleucel is used for acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL).
Treatment Given by InfusionDownloads:
Obecabtagene Autoleucel
Obecabtagene autoleucel is used for acute lymphoblastic leukemia (ALL).
Treatment Given by InfusionDownloads:
Ciltacabtagene Autoleucel
Ciltacabtagene autoleucel is used for multiple myeloma (MM).
Treatment Given by InfusionDownloads:
Idecabtagene Vicleucel
Idecabtagene vicleucel is used for multiple myeloma (MM).
Treatment Given by InfusionDownloads:
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
